Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
1 report, 1 independent
Updated Oct 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup reissued a market outperform rating and Leerink Partners began coverage on Rapport Therapeutics.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Leerink partners
U.S. investment bank
Related events
- Citigroup restated a buy rating on shares of Intensity Therapeutics.
- Citigroup maintained a market outperform rating for Ethos Technologies Inc. on November 6, 2026.
- Citigroup reaffirmed its market outperform rating for Pitney Bowes.
- Citigroup reissued a market outperform rating for Sphere Entertainment Co. stock.
- MarketBeat provided average rating data for the stock, and Citigroup began coverage on Whitehawk Therapeutics shares.